Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b
Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b
About this item
Full title
Author / Creator
Publisher
Darmstadt: Steinkopff-Verlag
Journal title
Language
English
Formats
Publication information
Publisher
Darmstadt: Steinkopff-Verlag
Subjects
More information
Scope and Contents
Contents
Background
The BENEFIT study examined interferon beta (IFNB)-1b treatment in patients with clinically isolated syndrome (CIS) and ≥ 2 clinically silent brain MRI lesions.
Methods
Subgroups of 468 patients (IFNB-1b:
n
= 292; placebo:
n
= 176) were created for demographics, clinical, laboratory, and MRI findings at onset. The 'na...
Alternative Titles
Full title
Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_69193261
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_69193261
Other Identifiers
ISSN
0340-5354
E-ISSN
1432-1459
DOI
10.1007/s00415-007-0733-2
